Peter Campbell | Head of Cancer, Ageing and Somatic Mutation, and Senior Group Leader

Campbell, Peter

peter.campbell@sanger.ac.uk
Cancer Genome Project

Peter Campbell's research programme focuses on the genetic changes our cells acquire as we go through life, and how these mutations are related to ageing, cancer and other disease processes.

My major interest is in cancer genomics, and in particular genome-wide analyses of somatic mutations in tumours. My major areas of interest have been: the discovery of new cancer genes; the identification of somatic mutation processes operative in tumours; the characterisation of patterns of cancer evolution; and the translation of these fundamental insights about cancer biology into better management of patients. I am increasingly interested in the role of somatic mutations outside of cancer. Particular focus areas include how somatic mutations delineate clonal relationships of normal cellular populations and how somatic mutations affect normal cellular behaviour.

Publications

  • Classification and Personalized Prognosis in Myeloproliferative Neoplasms.

    Grinfeld J, Nangalia J, Baxter EJ, Wedge DC, Angelopoulos N et al.

    The New England journal of medicine 2018;379;15;1416-1430

    PUBMED: 30304655; DOI: 10.1056/NEJMoa1716614

  • Population dynamics of normal human blood inferred from somatic mutations.

    Lee-Six H, Øbro NF, Shepherd MS, Grossmann S, Dawson K et al.

    Nature 2018;561;7724;473-478

    PUBMED: 30185910; PMC: 6163040; DOI: 10.1038/s41586-018-0497-0

  • Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal.

    Mitchell TJ, Turajlic S, Rowan A, Nicol D, Farmery JHR et al.

    Cell 2018;173;3;611-623.e17

    PUBMED: 29656891; PMC: 5927631; DOI: 10.1016/j.cell.2018.02.020

  • Universal Patterns of Selection in Cancer and Somatic Tissues.

    Martincorena I, Raine KM, Gerstung M, Dawson KJ, Haase K et al.

    Cell 2017;171;5;1029-1041.e21

    PUBMED: 29056346; PMC: 5720395; DOI: 10.1016/j.cell.2017.09.042

  • Precision oncology for acute myeloid leukemia using a knowledge bank approach.

    Gerstung M, Papaemmanuil E, Martincorena I, Bullinger L, Gaidzik VI et al.

    Nature genetics 2017;49;3;332-340

    PUBMED: 28092685; PMC: 5764082; DOI: 10.1038/ng.3756

  • Genomic Classification and Prognosis in Acute Myeloid Leukemia.

    Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P et al.

    The New England journal of medicine 2016;374;23;2209-2221

    PUBMED: 27276561; PMC: 4979995; DOI: 10.1056/NEJMoa1516192

  • Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin.

    Martincorena I, Roshan A, Gerstung M, Ellis P, Van Loo P et al.

    Science (New York, N.Y.) 2015;348;6237;880-6

    PUBMED: 25999502; PMC: 4471149; DOI: 10.1126/science.aaa6806

  • Subclonal diversification of primary breast cancer revealed by multiregion sequencing.

    Yates LR, Gerstung M, Knappskog S, Desmedt C, Gundem G et al.

    Nature medicine 2015;21;7;751-9

    PUBMED: 26099045; PMC: 4500826; DOI: 10.1038/nm.3886

  • Mobile DNA in cancer. Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes.

    Tubio JMC, Li Y, Ju YS, Martincorena I, Cooke SL et al.

    Science (New York, N.Y.) 2014;345;6196;1251343

    PUBMED: 25082706; PMC: 4380235; DOI: 10.1126/science.1251343

  • Recurrent PTPRB and PLCG1 mutations in angiosarcoma.

    Behjati S, Tarpey PS, Sheldon H, Martincorena I, Van Loo P et al.

    Nature genetics 2014;46;4;376-379

    PUBMED: 24633157; PMC: 4032873; DOI: 10.1038/ng.2921

  • RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia.

    Papaemmanuil E, Rapado I, Li Y, Potter NE, Wedge DC et al.

    Nature genetics 2014;46;2;116-25

    PUBMED: 24413735; PMC: 3960636; DOI: 10.1038/ng.2874

  • The life history of 21 breast cancers.

    Nik-Zainal S, Van Loo P, Wedge DC, Alexandrov LB, Greenman CD et al.

    Cell 2012;149;5;994-1007

    PUBMED: 22608083; PMC: 3428864; DOI: 10.1016/j.cell.2012.04.023

  • Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts.

    Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P et al.

    The New England journal of medicine 2011;365;15;1384-95

    PUBMED: 21995386; PMC: 3322589; DOI: 10.1056/NEJMoa1103283

  • Massive genomic rearrangement acquired in a single catastrophic event during cancer development.

    Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR et al.

    Cell 2011;144;1;27-40

    PUBMED: 21215367; PMC: 3065307; DOI: 10.1016/j.cell.2010.11.055

  • The patterns and dynamics of genomic instability in metastatic pancreatic cancer.

    Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED et al.

    Nature 2010;467;7319;1109-13

    PUBMED: 20981101; PMC: 3137369; DOI: 10.1038/nature09460

  • A small-cell lung cancer genome with complex signatures of tobacco exposure.

    Pleasance ED, Stephens PJ, O'Meara S, McBride DJ, Meynert A et al.

    Nature 2010;463;7278;184-90

    PUBMED: 20016488; PMC: 2880489; DOI: 10.1038/nature08629

  • Embryonal precursors of Wilms tumor.

    Coorens THH, Treger TD, Al-Saadi R, Moore L, Tran MGB et al.

    Science (New York, N.Y.) 2019;366;6470;1247-1251

    PUBMED: 31806814; PMC: 6914378; DOI: 10.1126/science.aax1323

  • Genome Sequencing during a Patient's Journey through Cancer.

    Nangalia J and Campbell PJ

    The New England journal of medicine 2019;381;22;2145-2156

    PUBMED: 31774959; DOI: 10.1056/NEJMra1910138

  • The landscape of somatic mutation in normal colorectal epithelial cells.

    Lee-Six H, Olafsson S, Ellis P, Osborne RJ, Sanders MA et al.

    Nature 2019;574;7779;532-537

    PUBMED: 31645730; DOI: 10.1038/s41586-019-1672-7

  • Somatic mutations and clonal dynamics in healthy and cirrhotic human liver.

    Brunner SF, Roberts ND, Wylie LA, Moore L, Aitken SJ et al.

    Nature 2019;574;7779;538-542

    PUBMED: 31645727; PMC: 6837891; DOI: 10.1038/s41586-019-1670-9

  • Cohesin-dependent regulation of gene expression during differentiation is lost in Cohesin-mutated myeloid malignancies.

    Sasca D, Yun H, Giotopoulos G, Szybinski J, Evan T et al.

    Blood 2019

    PUBMED: 31515253; DOI: 10.1182/blood.2019001553

  • Genomic landscape and chronological reconstruction of driver events in multiple myeloma.

    Maura F, Bolli N, Angelopoulos N, Dawson KJ, Leongamornlert D et al.

    Nature communications 2019;10;1;3835

    PUBMED: 31444325; PMC: 6707220; DOI: 10.1038/s41467-019-11680-1

  • Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down Syndrome.

    Labuhn M, Perkins K, Matzk S, Varghese L, Garnett C et al.

    Cancer cell 2019

    PUBMED: 31303423; DOI: 10.1016/j.ccell.2019.06.007

  • A practical guide for mutational signature analysis in hematological malignancies.

    Maura F, Degasperi A, Nadeu F, Leongamornlert D, Davies H et al.

    Nature communications 2019;10;1;2969

    PUBMED: 31278357; PMC: 6611883; DOI: 10.1038/s41467-019-11037-8

  • Integration of transcriptional and mutational data simplifies the stratification of peripheral T-cell lymphoma.

    Maura F, Agnelli L, Leongamornlert D, Bolli N, Chan WC et al.

    American journal of hematology 2019;94;6;628-634

    PUBMED: 30829413; PMC: 6684242; DOI: 10.1002/ajh.25450

  • Chromosome segregation errors generate a diverse spectrum of simple and complex genomic rearrangements.

    Ly P, Brunner SF, Shoshani O, Kim DH, Lan W et al.

    Nature genetics 2019;51;4;705-715

    PUBMED: 30833795; PMC: 6441390; DOI: 10.1038/s41588-019-0360-8; URL:

  • Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML.

    Basheer F, Giotopoulos G, Meduri E, Yun H, Mazan M et al.

    The Journal of experimental medicine 2019;216;4;966-981

    PUBMED: 30890554; PMC: 6446874; DOI: 10.1084/jem.20181276; URL:

  • Undifferentiated Sarcomas Develop through Distinct Evolutionary Pathways.

    Steele CD, Tarabichi M, Oukrif D, Webster AP, Ye H et al.

    Cancer cell 2019;35;3;441-456.e8

    PUBMED: 30889380; PMC: 6428691; DOI: 10.1016/j.ccell.2019.02.002

  • Characterizing Mutational Signatures in Human Cancer Cell Lines Reveals Episodic APOBEC Mutagenesis.

    Petljak M, Alexandrov LB, Brammeld JS, Price S, Wedge DC et al.

    Cell 2019;176;6;1282-1294.e20

    PUBMED: 30849372; PMC: 6424819; DOI: 10.1016/j.cell.2019.02.012

  • Deciphering the genomic, epigenomic, and transcriptomic landscapes of pre-invasive lung cancer lesions.

    Teixeira VH, Pipinikas CP, Pennycuick A, Lee-Six H, Chandrasekharan D et al.

    Nature medicine 2019;25;3;517-525

    PUBMED: 30664780; DOI: 10.1038/s41591-018-0323-0

  • Recurrent histone mutations in T-cell acute lymphoblastic leukaemia.

    Collord G, Martincorena I, Young MD, Foroni L, Bolli N et al.

    British journal of haematology 2019;184;4;676-679

    PUBMED: 29602208; PMC: 6766952; DOI: 10.1111/bjh.15155

  • TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups.

    Haase D, Stevenson KE, Neuberg D, Maciejewski JP, Nazha A et al.

    Leukemia 2019

    PUBMED: 30635634; DOI: 10.1038/s41375-018-0351-2

  • COSMIC: the Catalogue Of Somatic Mutations In Cancer.

    Tate JG, Bamford S, Jubb HC, Sondka Z, Beare DM et al.

    Nucleic acids research 2019;47;D1;D941-D947

    PUBMED: 30371878; PMC: 6323903; DOI: 10.1093/nar/gky1015

  • Single cell analysis of clonal architecture in acute myeloid leukaemia.

    Potter N, Miraki-Moud F, Ermini L, Titley I, Vijayaraghavan G et al.

    Leukemia 2018

    PUBMED: 30568172; DOI: 10.1038/s41375-018-0319-2

  • Neutral tumor evolution?

    Tarabichi M, Martincorena I, Gerstung M, Leroi AM, Markowetz F et al.

    Nature genetics 2018;50;12;1630-1633

    PUBMED: 30374075; PMC: 6548558; DOI: 10.1038/s41588-018-0258-x

  • Somatic mutant clones colonize the human esophagus with age.

    Martincorena I, Fowler JC, Wabik A, Lawson ARJ, Abascal F et al.

    Science (New York, N.Y.) 2018;362;6417;911-917

    PUBMED: 30337457; PMC: 6298579; DOI: 10.1126/science.aau3879

  • Integrative Molecular Characterization of Malignant Pleural Mesothelioma.

    Hmeljak J, Sanchez-Vega F, Hoadley KA, Shih J, Stewart C et al.

    Cancer discovery 2018

    PUBMED: 30322867; DOI: 10.1158/2159-8290.CD-18-0804

  • Classification and Personalized Prognosis in Myeloproliferative Neoplasms.

    Grinfeld J, Nangalia J, Baxter EJ, Wedge DC, Angelopoulos N et al.

    The New England journal of medicine 2018;379;15;1416-1430

    PUBMED: 30304655; DOI: 10.1056/NEJMoa1716614

  • Population dynamics of normal human blood inferred from somatic mutations.

    Lee-Six H, Øbro NF, Shepherd MS, Grossmann S, Dawson K et al.

    Nature 2018;561;7724;473-478

    PUBMED: 30185910; PMC: 6163040; DOI: 10.1038/s41586-018-0497-0

  • Rearrangement bursts generate canonical gene fusions in bone and soft tissue tumors.

    Anderson ND, de Borja R, Young MD, Fuligni F, Rosic A et al.

    Science (New York, N.Y.) 2018;361;6405

    PUBMED: 30166462; PMC: 6176908; DOI: 10.1126/science.aam8419

  • Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features.

    Godfrey AL, Campbell PJ, MacLean C, Buck G, Cook J et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018;JCO2018788414

    PUBMED: 30153096; DOI: 10.1200/JCO.2018.78.8414

  • Genomic patterns of progression in smoldering multiple myeloma.

    Bolli N, Maura F, Minvielle S, Gloznik D, Szalat R et al.

    Nature communications 2018;9;1;3363

    PUBMED: 30135448; DOI: 10.1038/s41467-018-05058-y

  • Prediction of acute myeloid leukaemia risk in healthy individuals.

    Abelson S, Collord G, Ng SWK, Weissbrod O, Mendelson Cohen N et al.

    Nature 2018;559;7714;400-404

    PUBMED: 29988082; PMC: 6485381; DOI: 10.1038/s41586-018-0317-6

  • Recurrent intragenic rearrangements of EGFR and BRAF in soft tissue tumors of infants.

    Wegert J, Vokuhl C, Collord G, Del Castillo Velasco-Herrera M, Farndon SJ et al.

    Nature communications 2018;9;1;2378

    PUBMED: 29915264; PMC: 6006309; DOI: 10.1038/s41467-018-04650-6

  • Recurrent rearrangements of FOS and FOSB define osteoblastoma.

    Fittall MW, Mifsud W, Pillay N, Ye H, Strobl AC et al.

    Nature communications 2018;9;1;2150

    PUBMED: 29858576; PMC: 5984627; DOI: 10.1038/s41467-018-04530-z

  • Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal.

    Turajlic S, Xu H, Litchfield K, Rowan A, Horswell S et al.

    Cell 2018;173;3;595-610.e11

    PUBMED: 29656894; PMC: 5938372; DOI: 10.1016/j.cell.2018.03.043

  • Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal.

    Mitchell TJ, Turajlic S, Rowan A, Nicol D, Farmery JHR et al.

    Cell 2018;173;3;611-623.e17

    PUBMED: 29656891; PMC: 5927631; DOI: 10.1016/j.cell.2018.02.020

  • Mutational signatures of DNA mismatch repair deficiency in C. elegans and human cancers.

    Meier B, Volkova NV, Hong Y, Schofield P, Campbell PJ et al.

    Genome research 2018

    PUBMED: 29636374; DOI: 10.1101/gr.226845.117

  • Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines.

    Maura F, Petljak M, Lionetti M, Cifola I, Liang W et al.

    Leukemia 2018;32;4;1044-1048

    PUBMED: 29209044; PMC: 5886048; DOI: 10.1038/leu.2017.345

  • Intra-tumour diversification in colorectal cancer at the single-cell level.

    Roerink SF, Sasaki N, Lee-Six H, Young MD, Alexandrov LB et al.

    Nature 2018;556;7702;457-462

    PUBMED: 29643510; DOI: 10.1038/s41586-018-0024-3

  • SvABA: genome-wide detection of structural variants and indels by local assembly.

    Wala JA, Bandopadhayay P, Greenwald NF, O'Rourke R, Sharpe T et al.

    Genome research 2018;28;4;581-591

    PUBMED: 29535149; PMC: 5880247; DOI: 10.1101/gr.221028.117

  • A Distinct Class of Genome Rearrangements Driven by Heterologous Recombination.

    León-Ortiz AM, Panier S, Sarek G, Vannier JB, Patel H et al.

    Molecular cell 2018;69;2;292-305.e6

    PUBMED: 29351848; DOI: 10.1016/j.molcel.2017.12.014

  • The European Society for Medical Oncology (ESMO) Precision Medicine Glossary.

    Yates LR, Seoane J, Le Tourneau C, Siu LL, Marais R et al.

    Annals of oncology : official journal of the European Society for Medical Oncology 2018;29;1;30-35

    PUBMED: 29140430; DOI: 10.1093/annonc/mdx707

  • Universal Patterns of Selection in Cancer and Somatic Tissues.

    Martincorena I, Raine KM, Gerstung M, Dawson KJ, Haase K et al.

    Cell 2017;171;5;1029-1041.e21

    PUBMED: 29056346; PMC: 5720395; DOI: 10.1016/j.cell.2017.09.042

  • Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors.

    Cheng J, Demeulemeester J, Wedge DC, Vollan HKM, Pitt JJ et al.

    Nature communications 2017;8;1;1221

    PUBMED: 29089486; DOI: 10.1038/s41467-017-01355-0

  • The driver landscape of sporadic chordoma.

    Tarpey PS, Behjati S, Young MD, Martincorena I, Alexandrov LB et al.

    Nature communications 2017;8;1;890

    PUBMED: 29026114; PMC: 5638846; DOI: 10.1038/s41467-017-01026-0

  • Next-generation sequencing of a family with a high penetrance of monoclonal gammopathies for the identification of candidate risk alleles.

    Bolli N, Barcella M, Salvi E, D'Avila F, Vendramin A et al.

    Cancer 2017;123;19;3701-3708

    PUBMED: 28542843; DOI: 10.1002/cncr.30777

  • Genomic Determinants of Protein Abundance Variation in Colorectal Cancer Cells.

    Roumeliotis TI, Williams SP, Gonçalves E, Alsinet C, Del Castillo Velasco-Herrera M et al.

    Cell reports 2017;20;9;2201-2214

    PUBMED: 28854368; PMC: 5583477; DOI: 10.1016/j.celrep.2017.08.010

  • Cliques and Schisms of Cancer Genes.

    Campbell PJ

    Cancer cell 2017;32;2;129-130

    PUBMED: 28810139; DOI: 10.1016/j.ccell.2017.07.009

  • Genomic Evolution of Breast Cancer Metastasis and Relapse.

    Yates LR, Knappskog S, Wedge D, Farmery JHR, Gonzalez S et al.

    Cancer cell 2017;32;2;169-184.e7

    PUBMED: 28810143; PMC: 5559645; DOI: 10.1016/j.ccell.2017.07.005

  • Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic Syndromes.

    Unnikrishnan A, Papaemmanuil E, Beck D, Deshpande NP, Verma A et al.

    Cell reports 2017;20;3;572-585

    PUBMED: 28723562; DOI: 10.1016/j.celrep.2017.06.067

  • Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma.

    Behjati S, Tarpey PS, Haase K, Ye H, Young MD et al.

    Nature communications 2017;8;15936

    PUBMED: 28643781; PMC: 5490007; DOI: 10.1038/ncomms15936

  • Somatic mutations reveal asymmetric cellular dynamics in the early human embryo.

    Ju YS, Martincorena I, Gerstung M, Petljak M, Alexandrov LB et al.

    Nature 2017;543;7647;714-718

    PUBMED: 28329761; PMC: 6169740; DOI: 10.1038/nature21703

  • A somatic-mutational process recurrently duplicates germline susceptibility loci and tissue-specific super-enhancers in breast cancers.

    Glodzik D, Morganella S, Davies H, Simpson PT, Li Y et al.

    Nature genetics 2017;49;3;341-348

    PUBMED: 28112740; PMC: 5988034; DOI: 10.1038/ng.3771

  • Precision oncology for acute myeloid leukemia using a knowledge bank approach.

    Gerstung M, Papaemmanuil E, Martincorena I, Bullinger L, Gaidzik VI et al.

    Nature genetics 2017;49;3;332-340

    PUBMED: 28092685; PMC: 5764082; DOI: 10.1038/ng.3756

  • COSMIC: somatic cancer genetics at high-resolution.

    Forbes SA, Beare D, Boutselakis H, Bamford S, Bindal N et al.

    Nucleic acids research 2017;45;D1;D777-D783

    PUBMED: 27899578; PMC: 5210583; DOI: 10.1093/nar/gkw1121

  • Sources of error in measurement of minimal residual disease in childhood acute lymphoblastic leukemia.

    Latham S, Hughes E, Budgen B, Mechinaud F, Crock C et al.

    PloS one 2017;12;10;e0185556

    PUBMED: 28973007; DOI: 10.1371/journal.pone.0185556

  • ascatNgs: Identifying Somatically Acquired Copy-Number Alterations from Whole-Genome Sequencing Data.

    Raine KM, Van Loo P, Wedge DC, Jones D, Menzies A et al.

    Current protocols in bioinformatics 2016;56;15.9.1-15.9.17

    PUBMED: 27930809; PMC: 6097604; DOI: 10.1002/cpbi.17

  • Mutational signatures associated with tobacco smoking in human cancer.

    Alexandrov LB, Ju YS, Haase K, Van Loo P, Martincorena I et al.

    Science (New York, N.Y.) 2016;354;6312;618-622

    PUBMED: 27811275; PMC: 6141049; DOI: 10.1126/science.aag0299

  • RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features.

    Gaidzik VI, Teleanu V, Papaemmanuil E, Weber D, Paschka P et al.

    Leukemia 2016;30;11;2160-2168

    PUBMED: 27137476; DOI: 10.1038/leu.2016.126

  • A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns.

    Notta F, Chan-Seng-Yue M, Lemire M, Li Y, Wilson GW et al.

    Nature 2016;538;7625;378-382

    PUBMED: 27732578; PMC: 5446075; DOI: 10.1038/nature19823

  • COSMIC: High-Resolution Cancer Genetics Using the Catalogue of Somatic Mutations in Cancer.

    Forbes SA, Beare D, Bindal N, Bamford S, Ward S et al.

    Current protocols in human genetics 2016;91;10.11.1-10.11.37

    PUBMED: 27727438; DOI: 10.1002/cphg.21

  • Mutational signatures of ionizing radiation in second malignancies.

    Behjati S, Gundem G, Wedge DC, Roberts ND, Tarpey PS et al.

    Nature communications 2016;7;12605

    PUBMED: 27615322; PMC: 5027243; DOI: 10.1038/ncomms12605

  • A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma.

    Bolli N, Li Y, Sathiaseelan V, Raine K, Jones D et al.

    Blood cancer journal 2016;6;9;e467

    PUBMED: 27588520; PMC: 5056967; DOI: 10.1038/bcj.2016.72

  • Genomic Classification in Acute Myeloid Leukemia.

    Papaemmanuil E, Döhner H and Campbell PJ

    The New England journal of medicine 2016;375;9;900-1

    PUBMED: 27579651; DOI: 10.1056/NEJMc1608739

  • Direct Transcriptional Consequences of Somatic Mutation in Breast Cancer.

    Shlien A, Raine K, Fuligni F, Arnold R, Nik-Zainal S et al.

    Cell reports 2016;16;7;2032-46

    PUBMED: 27498871; PMC: 4987284; DOI: 10.1016/j.celrep.2016.07.028

  • Impact of socioeconomic status on disease phenotype, genomic landscape and outcomes in myelodysplastic syndromes.

    Mastaglio F, Bedair K, Papaemmanuil E, Groves MJ, Hyslop A et al.

    British journal of haematology 2016;174;2;227-34

    PUBMED: 27098194; DOI: 10.1111/bjh.14042

  • Genomic Classification and Prognosis in Acute Myeloid Leukemia.

    Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P et al.

    The New England journal of medicine 2016;374;23;2209-2221

    PUBMED: 27276561; PMC: 4979995; DOI: 10.1056/NEJMoa1516192

  • Landscape of somatic mutations in 560 breast cancer whole-genome sequences.

    Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D et al.

    Nature 2016;534;7605;47-54

    PUBMED: 27135926; PMC: 4910866; DOI: 10.1038/nature17676

  • Genomic Characterization of Primary Invasive Lobular Breast Cancer.

    Desmedt C, Zoppoli G, Gundem G, Pruneri G, Larsimont D et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016;34;16;1872-81

    PUBMED: 26926684; DOI: 10.1200/JCO.2015.64.0334

  • The topography of mutational processes in breast cancer genomes.

    Morganella S, Alexandrov LB, Glodzik D, Zou X, Davies H et al.

    Nature communications 2016;7;11383

    PUBMED: 27136393; PMC: 5001788; DOI: 10.1038/ncomms11383

  • Constrained positive selection on cancer mutations in normal skin.

    Martincorena I, Jones PH and Campbell PJ

    Proceedings of the National Academy of Sciences of the United States of America 2016;113;9;E1128-9

    PUBMED: 26884187; PMC: 4780655; DOI: 10.1073/pnas.1600910113

  • Unscrambling the genomic chaos of osteosarcoma reveals extensive transcript fusion, recurrent rearrangements and frequent novel TP53 aberrations.

    Lorenz S, Barøy T, Sun J, Nome T, Vodák D et al.

    Oncotarget 2016;7;5;5273-88

    PUBMED: 26672768; DOI: 10.18632/oncotarget.6567

  • Modeling the evolution space of breakage fusion bridge cycles with a stochastic folding process.

    Greenman CD, Cooke SL, Marshall J, Stratton MR and Campbell PJ

    Journal of mathematical biology 2016;72;1-2;47-86

    PUBMED: 25833184; PMC: 4702116; DOI: 10.1007/s00285-015-0875-2

  • cgpPindel: Identifying Somatically Acquired Insertion and Deletion Events from Paired End Sequencing.

    Raine KM, Hinton J, Butler AP, Teague JW, Davies H et al.

    Current protocols in bioinformatics 2015;52;15.7.1-15.7.12

    PUBMED: 26678382; PMC: 6097606; DOI: 10.1002/0471250953.bi1507s52

  • Chromothripsis and Kataegis Induced by Telomere Crisis.

    Maciejowski J, Li Y, Bosco N, Campbell PJ and de Lange T

    Cell 2015;163;7;1641-54

    PUBMED: 26687355; PMC: 4687025; DOI: 10.1016/j.cell.2015.11.054

  • VAGrENT: Variation Annotation Generator.

    Menzies A, Teague JW, Butler AP, Davies H, Tarpey P et al.

    Current protocols in bioinformatics 2015;52;15.8.1-15.8.11

    PUBMED: 26678383; PMC: 6101192; DOI: 10.1002/0471250953.bi1508s52

  • Clock-like mutational processes in human somatic cells.

    Alexandrov LB, Jones PH, Wedge DC, Sale JE, Campbell PJ et al.

    Nature genetics 2015;47;12;1402-7

    PUBMED: 26551669; PMC: 4783858; DOI: 10.1038/ng.3441

  • Aberrant splicing of genes involved in haemoglobin synthesis and impaired terminal erythroid maturation in SF3B1 mutated refractory anaemia with ring sideroblasts.

    Conte S, Katayama S, Vesterlund L, Karimi M, Dimitriou M et al.

    British journal of haematology 2015;171;4;478-90

    PUBMED: 26255870; PMC: 4832260; DOI: 10.1111/bjh.13610

  • DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype.

    Nangalia J, Nice FL, Wedge DC, Godfrey AL, Grinfeld J et al.

    Haematologica 2015;100;11;e438-42

    PUBMED: 26250577; PMC: 4825297; DOI: 10.3324/haematol.2015.129510

  • Principles Governing A-to-I RNA Editing in the Breast Cancer Transcriptome.

    Fumagalli D, Gacquer D, Rothé F, Lefort A, Libert F et al.

    Cell reports 2015;13;2;277-89

    PUBMED: 26440892; DOI: 10.1016/j.celrep.2015.09.032

  • Somatic mutation in cancer and normal cells.

    Martincorena I and Campbell PJ

    Science (New York, N.Y.) 2015;349;6255;1483-9

    PUBMED: 26404825; DOI: 10.1126/science.aab4082

  • Uncovering the genomic heterogeneity of multifocal breast cancer.

    Desmedt C, Fumagalli D, Pietri E, Zoppoli G, Brown D et al.

    The Journal of pathology 2015;236;4;457-66

    PUBMED: 25850943; PMC: 4691324; DOI: 10.1002/path.4540

  • Data analysis: Create a cloud commons.

    Stein LD, Knoppers BM, Campbell P, Getz G and Korbel JO

    Nature 2015;523;7559;149-51

    PUBMED: 26156357; DOI: 10.1038/523149a

  • SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts.

    Malcovati L, Karimi M, Papaemmanuil E, Ambaglio I, Jädersten M et al.

    Blood 2015;126;2;233-41

    PUBMED: 25957392; PMC: 4528082; DOI: 10.1182/blood-2015-03-633537

  • Subclonal diversification of primary breast cancer revealed by multiregion sequencing.

    Yates LR, Gerstung M, Knappskog S, Desmedt C, Gundem G et al.

    Nature medicine 2015;21;7;751-9

    PUBMED: 26099045; PMC: 4500826; DOI: 10.1038/nm.3886

  • Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells.

    Ju YS, Tubio JM, Mifsud W, Fu B, Davies HR et al.

    Genome research 2015;25;6;814-24

    PUBMED: 25963125; PMC: 4448678; DOI: 10.1101/gr.190470.115

  • Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin.

    Martincorena I, Roshan A, Gerstung M, Ellis P, Van Loo P et al.

    Science (New York, N.Y.) 2015;348;6237;880-6

    PUBMED: 25999502; PMC: 4471149; DOI: 10.1126/science.aaa6806

  • Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells.

    Dolatshad H, Pellagatti A, Fernandez-Mercado M, Yip BH, Malcovati L et al.

    Leukemia 2015;29;5;1092-103

    PUBMED: 25428262; PMC: 4430703; DOI: 10.1038/leu.2014.331

  • The epigenetic regulators CBP and p300 facilitate leukemogenesis and represent therapeutic targets in acute myeloid leukemia.

    Giotopoulos G, Chan WI, Horton SJ, Ruau D, Gallipoli P et al.

    Oncogene 2015

    PUBMED: 25893291; DOI: 10.1038/onc.2015.92

  • The evolutionary history of lethal metastatic prostate cancer.

    Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JMC et al.

    Nature 2015;520;7547;353-357

    PUBMED: 25830880; PMC: 4413032; DOI: 10.1038/nature14347

  • Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue.

    Cooper CS, Eeles R, Wedge DC, Van Loo P, Gundem G et al.

    Nature genetics 2015;47;4;367-372

    PUBMED: 25730763; PMC: 4380509; DOI: 10.1038/ng.3221

  • Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers.

    Shlien A, Campbell BB, de Borja R, Alexandrov LB, Merico D et al.

    Nature genetics 2015;47;3;257-62

    PUBMED: 25642631; DOI: 10.1038/ng.3202

  • Effect of mutation order on myeloproliferative neoplasms.

    Ortmann CA, Kent DG, Nangalia J, Silber Y, Wedge DC et al.

    The New England journal of medicine 2015;372;7;601-612

    PUBMED: 25671252; PMC: 4660033; DOI: 10.1056/NEJMoa1412098

  • Characterization of gene mutations and copy number changes in acute myeloid leukemia using a rapid target enrichment protocol.

    Bolli N, Manes N, McKerrell T, Chi J, Park N et al.

    Haematologica 2015;100;2;214-22

    PUBMED: 25381129; PMC: 4803131; DOI: 10.3324/haematol.2014.113381

  • Recurrent ETNK1 mutations in atypical chronic myeloid leukemia.

    Gambacorti-Passerini CB, Donadoni C, Parmiani A, Pirola A, Redaelli S et al.

    Blood 2015;125;3;499-503

    PUBMED: 25343957; DOI: 10.1182/blood-2014-06-579466

  • A comprehensive assessment of somatic mutation detection in cancer using whole-genome sequencing.

    Alioto TS, Buchhalter I, Derdak S, Hutter B, Eldridge MD et al.

    Nature communications 2015;6;10001

    PUBMED: 26647970; PMC: 4682041; DOI: 10.1038/ncomms10001

  • Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes.

    Gerstung M, Pellagatti A, Malcovati L, Giagounidis A, Porta MG et al.

    Nature communications 2015;6;5901

    PUBMED: 25574665; PMC: 4338540; DOI: 10.1038/ncomms6901

  • COSMIC: exploring the world's knowledge of somatic mutations in human cancer.

    Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N et al.

    Nucleic acids research 2015;43;Database issue;D805-11

    PUBMED: 25355519; PMC: 4383913; DOI: 10.1093/nar/gku1075

  • Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms.

    Tapper W, Jones AV, Kralovics R, Harutyunyan AS, Zoi K et al.

    Nature communications 2015;6;6691

    PUBMED: 25849990; PMC: 4396373; DOI: 10.1038/ncomms7691

  • High Throughput Sequencing Analysis of the Immunoglobulin Heavy Chain Gene from Flow-Sorted B Cell Sub-Populations Define the Dynamics of Follicular Lymphoma Clonal Evolution.

    Carlotti E, Wrench D, Rosignoli G, Marzec J, Sangaralingam A et al.

    PloS one 2015;10;9;e0134833

    PUBMED: 26325507; PMC: 4556522; DOI: 10.1371/journal.pone.0134833

  • Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes.

    Della Porta MG, Travaglino E, Boveri E, Ponzoni M, Malcovati L et al.

    Leukemia 2015;29;1;66-75

    PUBMED: 24935723; DOI: 10.1038/leu.2014.161

  • Nongenetic stochastic expansion of JAK2V617F-homozygous subclones in polycythemia vera?

    Godfrey AL, Nangalia J, Baxter EJ, Massie CE, Kent DG et al.

    Blood 2014;124;22;3332-4

    PUBMED: 25414437; PMC: 4239339; DOI: 10.1182/blood-2014-09-603043

  • The AURORA initiative for metastatic breast cancer.

    Zardavas D, Maetens M, Irrthum A, Goulioti T, Engelen K et al.

    British journal of cancer 2014;111;10;1881-7

    PUBMED: 25225904; PMC: 4229627; DOI: 10.1038/bjc.2014.341

  • Modification of British Committee for Standards in Haematology diagnostic criteria for essential thrombocythaemia.

    Harrison CN, Butt N, Campbell P, Conneally E, Drummond M et al.

    British journal of haematology 2014;167;3;421-3

    PUBMED: 24935860; DOI: 10.1111/bjh.12986

  • Genomic catastrophes frequently arise in esophageal adenocarcinoma and drive tumorigenesis.

    Nones K, Waddell N, Wayte N, Patch AM, Bailey P et al.

    Nature communications 2014;5;5224

    PUBMED: 25351503; PMC: 4596003; DOI: 10.1038/ncomms6224

  • Spatial and temporal diversity in genomic instability processes defines lung cancer evolution.

    de Bruin EC, McGranahan N, Mitter R, Salm M, Wedge DC et al.

    Science (New York, N.Y.) 2014;346;6206;251-6

    PUBMED: 25301630; PMC: 4636050; DOI: 10.1126/science.1253462

  • C. elegans whole-genome sequencing reveals mutational signatures related to carcinogens and DNA repair deficiency.

    Meier B, Cooke SL, Weiss J, Bailly AP, Alexandrov LB et al.

    Genome research 2014;24;10;1624-36

    PUBMED: 25030888; PMC: 4199376; DOI: 10.1101/gr.175547.114

  • Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer.

    Ju YS, Alexandrov LB, Gerstung M, Martincorena I, Nik-Zainal S et al.

    eLife 2014;3

    PUBMED: 25271376; PMC: 4371858; DOI: 10.7554/eLife.02935

  • Genome sequencing of normal cells reveals developmental lineages and mutational processes.

    Behjati S, Huch M, van Boxtel R, Karthaus W, Wedge DC et al.

    Nature 2014;513;7518;422-425

    PUBMED: 25043003; PMC: 4227286; DOI: 10.1038/nature13448

  • Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia.

    Malcovati L, Papaemmanuil E, Ambaglio I, Elena C, Gallì A et al.

    Blood 2014;124;9;1513-21

    PUBMED: 24970933; PMC: 4148773; DOI: 10.1182/blood-2014-03-560227

  • Fibroblastic growth factor receptor 1 amplification in osteosarcoma is associated with poor response to neo-adjuvant chemotherapy.

    Fernanda Amary M, Ye H, Berisha F, Khatri B, Forbes G et al.

    Cancer medicine 2014;3;4;980-7

    PUBMED: 24861215; PMC: 4303166; DOI: 10.1002/cam4.268

  • Mobile DNA in cancer. Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes.

    Tubio JMC, Li Y, Ju YS, Martincorena I, Cooke SL et al.

    Science (New York, N.Y.) 2014;345;6196;1251343

    PUBMED: 25082706; PMC: 4380235; DOI: 10.1126/science.1251343

  • Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo.

    Woll PS, Kjällquist U, Chowdhury O, Doolittle H, Wedge DC et al.

    Cancer cell 2014;25;6;794-808

    PUBMED: 24835589; DOI: 10.1016/j.ccr.2014.03.036

  • Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer.

    Nik-Zainal S, Wedge DC, Alexandrov LB, Petljak M, Butler AP et al.

    Nature genetics 2014;46;5;487-91

    PUBMED: 24728294; PMC: 4137149; DOI: 10.1038/ng.2955

  • Subclonal variant calling with multiple samples and prior knowledge.

    Gerstung M, Papaemmanuil E and Campbell PJ

    Bioinformatics (Oxford, England) 2014;30;9;1198-204

    PUBMED: 24443148; PMC: 3998123; DOI: 10.1093/bioinformatics/btt750

  • Processed pseudogenes acquired somatically during cancer development.

    Cooke SL, Shlien A, Marshall J, Pipinikas CP, Martincorena I et al.

    Nature communications 2014;5;3644

    PUBMED: 24714652; PMC: 3996531; DOI: 10.1038/ncomms4644

  • Constitutional and somatic rearrangement of chromosome 21 in acute lymphoblastic leukaemia.

    Li Y, Schwab C, Ryan S, Papaemmanuil E, Robinson HM et al.

    Nature 2014;508;7494;98-102

    PUBMED: 24670643; PMC: 3976272; DOI: 10.1038/nature13115

  • Recurrent PTPRB and PLCG1 mutations in angiosarcoma.

    Behjati S, Tarpey PS, Sheldon H, Martincorena I, Van Loo P et al.

    Nature genetics 2014;46;4;376-379

    PUBMED: 24633157; PMC: 4032873; DOI: 10.1038/ng.2921

  • RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia.

    Papaemmanuil E, Rapado I, Li Y, Potter NE, Wedge DC et al.

    Nature genetics 2014;46;2;116-25

    PUBMED: 24413735; PMC: 3960636; DOI: 10.1038/ng.2874

  • Transmissible [corrected] dog cancer genome reveals the origin and history of an ancient cell lineage.

    Murchison EP, Wedge DC, Alexandrov LB, Fu B, Martincorena I et al.

    Science (New York, N.Y.) 2014;343;6169;437-440

    PUBMED: 24458646; PMC: 3918581; DOI: 10.1126/science.1247167

  • Heterogeneity of genomic evolution and mutational profiles in multiple myeloma.

    Bolli N, Avet-Loiseau H, Wedge DC, Van Loo P, Alexandrov LB et al.

    Nature communications 2014;5;2997

    PUBMED: 24429703; PMC: 3905727; DOI: 10.1038/ncomms3997

  • Inactivating CUX1 mutations promote tumorigenesis.

    Wong CC, Martincorena I, Rust AG, Rashid M, Alifrangis C et al.

    Nature genetics 2014;46;1;33-8

    PUBMED: 24316979; PMC: 3874239; DOI: 10.1038/ng.2846

  • OncoCis: annotation of cis-regulatory mutations in cancer.

    Perera D, Chacon D, Thoms JA, Poulos RC, Shlien A et al.

    Genome biology 2014;15;10;485

    PUBMED: 25298093; PMC: 4224696; DOI: 10.1186/s13059-014-0485-0

  • Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.

    Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G et al.

    The New England journal of medicine 2013;369;25;2391-2405

    PUBMED: 24325359; PMC: 3966280; DOI: 10.1056/NEJMoa1312542

  • GATA1-mutant clones are frequent and often unsuspected in babies with Down syndrome: identification of a population at risk of leukemia.

    Roberts I, Alford K, Hall G, Juban G, Richmond H et al.

    Blood 2013;122;24;3908-17

    PUBMED: 24021668; PMC: 3995281; DOI: 10.1182/blood-2013-07-515148

  • Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone.

    Behjati S, Tarpey PS, Presneau N, Scheipl S, Pillay N et al.

    Nature genetics 2013;45;12;1479-82

    PUBMED: 24162739; PMC: 3839851; DOI: 10.1038/ng.2814

  • Single-cell mutational profiling and clonal phylogeny in cancer.

    Potter NE, Ermini L, Papaemmanuil E, Cazzaniga G, Vijayaraghavan G et al.

    Genome research 2013;23;12;2115-25

    PUBMED: 24056532; PMC: 3847780; DOI: 10.1101/gr.159913.113

  • Clinical and biological implications of driver mutations in myelodysplastic syndromes.

    Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G et al.

    Blood 2013;122;22;3616-27; quiz 3699

    PUBMED: 24030381; PMC: 3837510; DOI: 10.1182/blood-2013-08-518886

  • Signatures of mutational processes in human cancer.

    Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S et al.

    Nature 2013;500;7463;415-21

    PUBMED: 23945592; PMC: 3776390; DOI: 10.1038/nature12477

  • Frequent mutation of the major cartilage collagen gene COL2A1 in chondrosarcoma.

    Tarpey PS, Behjati S, Cooke SL, Van Loo P, Wedge DC et al.

    Nature genetics 2013;45;8;923-6

    PUBMED: 23770606; PMC: 3743157; DOI: 10.1038/ng.2668

  • Single-cell paired-end genome sequencing reveals structural variation per cell cycle.

    Voet T, Kumar P, Van Loo P, Cooke SL, Marshall J et al.

    Nucleic acids research 2013;41;12;6119-38

    PUBMED: 23630320; PMC: 3695511; DOI: 10.1093/nar/gkt345

  • Whole exome sequencing of adenoid cystic carcinoma.

    Stephens PJ, Davies HR, Mitani Y, Van Loo P, Shlien A et al.

    The Journal of clinical investigation 2013;123;7;2965-8

    PUBMED: 23778141; PMC: 3999050; DOI: 10.1172/JCI67201

  • Clonal analyses reveal associations of JAK2V617F homozygosity with hematologic features, age and gender in polycythemia vera and essential thrombocythemia.

    Godfrey AL, Chen E, Pagano F, Silber Y, Campbell PJ and Green AR

    Haematologica 2013;98;5;718-21

    PUBMED: 23633544; PMC: 3640115; DOI: 10.3324/haematol.2012.079129

  • Cooperativity of imprinted genes inactivated by acquired chromosome 20q deletions.

    Aziz A, Baxter EJ, Edwards C, Cheong CY, Ito M et al.

    The Journal of clinical investigation 2013;123;5;2169-82

    PUBMED: 23543057; PMC: 3635733; DOI: 10.1172/JCI66113

  • EMu: probabilistic inference of mutational processes and their localization in the cancer genome.

    Fischer A, Illingworth CJ, Campbell PJ and Mustonen V

    Genome biology 2013;14;4;R39

    PUBMED: 23628380; PMC: 3663107; DOI: 10.1186/gb-2013-14-4-r39

  • DNA deaminases induce break-associated mutation showers with implication of APOBEC3B and 3A in breast cancer kataegis.

    Taylor BJ, Nik-Zainal S, Wu YL, Stebbings LA, Raine K et al.

    eLife 2013;2;e00534

    PUBMED: 23599896; PMC: 3628087; DOI: 10.7554/eLife.00534

  • Aberrant 3' oligoadenylation of spliceosomal U6 small nuclear RNA in poikiloderma with neutropenia.

    Hilcenko C, Simpson PJ, Finch AJ, Bowler FR, Churcher MJ et al.

    Blood 2013;121;6;1028-38

    PUBMED: 23190533; DOI: 10.1182/blood-2012-10-461491

  • Deciphering signatures of mutational processes operative in human cancer.

    Alexandrov LB, Nik-Zainal S, Wedge DC, Campbell PJ and Stratton MR

    Cell reports 2013;3;1;246-59

    PUBMED: 23318258; PMC: 3588146; DOI: 10.1016/j.celrep.2012.12.008

  • The genetic heterogeneity and mutational burden of engineered melanomas in zebrafish models.

    Yen J, White RM, Wedge DC, Van Loo P, de Ridder J et al.

    Genome biology 2013;14;10;R113

    PUBMED: 24148783; PMC: 3983654; DOI: 10.1186/gb-2013-14-10-r113

  • Next-generation sequencing in breast cancer: first take home messages.

    Desmedt C, Voet T, Sotiriou C and Campbell PJ

    Current opinion in oncology 2012;24;6;597-604

    PUBMED: 23014189; PMC: 3713550; DOI: 10.1097/CCO.0b013e328359554e

  • JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone.

    Godfrey AL, Chen E, Pagano F, Ortmann CA, Silber Y et al.

    Blood 2012;120;13;2704-7

    PUBMED: 22898600; PMC: 3672970; DOI: 10.1182/blood-2012-05-431791

  • LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin.

    Cowin PA, George J, Fereday S, Loehrer E, Van Loo P et al.

    Cancer research 2012;72;16;4060-73

    PUBMED: 22896685; DOI: 10.1158/0008-5472.CAN-12-0203

  • The life history of 21 breast cancers.

    Nik-Zainal S, Van Loo P, Wedge DC, Alexandrov LB, Greenman CD et al.

    Cell 2012;149;5;994-1007

    PUBMED: 22608083; PMC: 3428864; DOI: 10.1016/j.cell.2012.04.023

  • The landscape of cancer genes and mutational processes in breast cancer.

    Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C et al.

    Nature 2012;486;7403;400-4

    PUBMED: 22722201; PMC: 3428862; DOI: 10.1038/nature11017

  • Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts.

    Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P et al.

    The New England journal of medicine 2011;365;15;1384-95

    PUBMED: 21995386; PMC: 3322589; DOI: 10.1056/NEJMoa1103283

  • Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma.

    Varela I, Tarpey P, Raine K, Huang D, Ong CK et al.

    Nature 2011;469;7331;539-42

    PUBMED: 21248752; PMC: 3030920; DOI: 10.1038/nature09639

  • Massive genomic rearrangement acquired in a single catastrophic event during cancer development.

    Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR et al.

    Cell 2011;144;1;27-40

    PUBMED: 21215367; PMC: 3065307; DOI: 10.1016/j.cell.2010.11.055

  • The patterns and dynamics of genomic instability in metastatic pancreatic cancer.

    Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED et al.

    Nature 2010;467;7319;1109-13

    PUBMED: 20981101; PMC: 3137369; DOI: 10.1038/nature09460

  • International network of cancer genome projects.

    International Cancer Genome Consortium, Hudson TJ, Anderson W, Artez A, Barker AD et al.

    Nature 2010;464;7291;993-8

    PUBMED: 20393554; PMC: 2902243; DOI: 10.1038/nature08987

  • Origins and functional impact of copy number variation in the human genome.

    Conrad DF, Pinto D, Redon R, Feuk L, Gokcumen O et al.

    Nature 2010;464;7289;704-12

    PUBMED: 19812545; PMC: 3330748; DOI: 10.1038/nature08516

  • Signatures of mutation and selection in the cancer genome.

    Bignell GR, Greenman CD, Davies H, Butler AP, Edkins S et al.

    Nature 2010;463;7283;893-8

    PUBMED: 20164919; PMC: 3145113; DOI: 10.1038/nature08768

  • Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes.

    Dalgliesh GL, Furge K, Greenman C, Chen L, Bignell G et al.

    Nature 2010;463;7279;360-3

    PUBMED: 20054297; PMC: 2820242; DOI: 10.1038/nature08672

  • A comprehensive catalogue of somatic mutations from a human cancer genome.

    Pleasance ED, Cheetham RK, Stephens PJ, McBride DJ, Humphray SJ et al.

    Nature 2010;463;7278;191-6

    PUBMED: 20016485; PMC: 3145108; DOI: 10.1038/nature08658

  • A small-cell lung cancer genome with complex signatures of tobacco exposure.

    Pleasance ED, Stephens PJ, O'Meara S, McBride DJ, Meynert A et al.

    Nature 2010;463;7278;184-90

    PUBMED: 20016488; PMC: 2880489; DOI: 10.1038/nature08629

  • Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer.

    van Haaften G, Dalgliesh GL, Davies H, Chen L, Bignell G et al.

    Nature genetics 2009;41;5;521-3

    PUBMED: 19330029; PMC: 2873835; DOI: 10.1038/ng.349

  • The cancer genome.

    Stratton MR, Campbell PJ and Futreal PA

    Nature 2009;458;7239;719-24

    PUBMED: 19360079; PMC: 2821689; DOI: 10.1038/nature07943

  • Somatic and germline genetics at the JAK2 locus.

    Campbell PJ

    Nature genetics 2009;41;4;385-6

    PUBMED: 19338077

  • Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing.

    Campbell PJ, Pleasance ED, Stephens PJ, Dicks E, Rance R et al.

    Proceedings of the National Academy of Sciences of the United States of America 2008;105;35;13081-6

    PUBMED: 18723673; PMC: 2529122; DOI: 10.1073/pnas.0801523105

  • Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing.

    Campbell PJ, Stephens PJ, Pleasance ED, O'Meara S, Li H et al.

    Nature genetics 2008;40;6;722-9

    PUBMED: 18438408; PMC: 2705838; DOI: 10.1038/ng.128

  • Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers.

    Maser RS, Choudhury B, Campbell PJ, Feng B, Wong KK et al.

    Nature 2007;447;7147;966-71

    PUBMED: 17515920; PMC: 2714968; DOI: 10.1038/nature05886

  • Patterns of somatic mutation in human cancer genomes.

    Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C et al.

    Nature 2007;446;7132;153-8

    PUBMED: 17344846; PMC: 2712719; DOI: 10.1038/nature05610

  • An acquired translocation in JAK2 Val617Phe-negative essential thrombocythemia associated with autosomal spread of X-inactivation.

    Vassiliou GS, Campbell PJ, Li J, Roberts I, Swanton S et al.

    Haematologica 2006;91;8;1100-4

    PUBMED: 16885051

  • Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.

    Campbell PJ, Scott LM, Buck G, Wheatley K, East CL et al.

    Lancet (London, England) 2005;366;9501;1945-53

    PUBMED: 16325696; DOI: 10.1016/S0140-6736(05)67785-9

  • Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.

    Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N et al.

    Lancet (London, England) 2005;365;9464;1054-61

    PUBMED: 15781101; DOI: 10.1016/S0140-6736(05)71142-9

Campbell, Peter

Related Programmes, Associate Research Programmes and Facilities

Peter's Timeline
2010

Group Leader, Wellcome Trust Sanger Institute

2007

Post-doctoral fellowship, Sanger Institute

2003

PhD studentship, University of Cambridge

2000

Clinical Haematology specialist training